By Michael Susin

GSK said that it has reached a confidential settlement in the Cantlay/Harper case filed in California state court over claims that its heartburn medicine Zantac can cause cancer.

The British pharmaceutical giant said Wednesday that the case, which was set to begin trial on Nov. 13, will be dismissed.

The company said it has also settled the three remaining breast cancer bellwether cases in California, and will be dismissed from these cases.

"The settlements reflect the company's desire to avoid the distraction related to protracted litigation. GSK does not admit any liability in the settlements and will continue to vigorously defend itself based on the facts and the science in all other Zantac cases," GSK said.

Write to Michael Susin at michael.susin@wsj.com

(END) Dow Jones Newswires

October 11, 2023 02:31 ET (06:31 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
GSK (NYSE:GSK)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024 Click aqui para mais gráficos GSK.
GSK (NYSE:GSK)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024 Click aqui para mais gráficos GSK.